Sara Rattotti

Sara Rattotti

Auto-generated profile, based on publicly available information

Sara Rattotti

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2016 in Blood
Verified
Journal Article
Closed access
PDF file
LALuca Arcaini
Luca Arcaini
CBCaroline Besson
Caroline Besson
MFMarco Frigeni
Marco Frigeni
HFHélène Fontaine
Hélène Fontaine
MGMaria Goldaniga
Maria Goldaniga
OHOlivier Hermine
Olivier Hermine
Regression of hepatitis C virus (HCV)–associated lymphoma with interferon (IFN)-based antiviral treatment supports an etiological link between lymphoma and HCV infection. In addition, a favorable impact of antiviral treatment on overall survival of patients with HCV-related lymphoma has been reported. Data on IFN-free regimens combining direct-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty. We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leukemia (CLL) and chronic HCV infection treated with DAAs. The histological distribution was 37 marginal zone lymphomas (MZLs), 2 lymphoplasmacytic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade NHL not otherwise specified. Thirty-nine patients received a sofosbuvir-based regimen and 7 patients received other DAAs. The median duration of DAA therapy was 12 weeks (range, 6-24 weeks). A sustained virological response at week 12 after finishing DAAs was obtained in 45 patients (98%); the overall LDR rate was 67%, including 12 patients (26%) who achieved a complete response. The LDR rate was 73% among patients with MZL, whereas no response was observed in CLL/SLL patients. Seven patients cleared cryoglobulins out of 15 who were initially positive. After a median follow-up of 8 months, 1-year progression-free and overall survival rates were 75% (95% confidence interval [CI], 51-88] and 98% [95% CI, 86-100], respectively. DAA therapy induces a high LDR rate in HCV-associated indolent lymphomas. These data provide a strong rationale for prospective trials with DAAs in this setting. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Direct-acting antiviral agents are able to induce lymphoma response in patients with HCV-associated indolent non-Hodgkin lymphoma. The highest rate of lymphoma response (73%) was observed in patients with marginal zone lymphoma.

23 January 2020 in Blood
Verified
Journal Article
Closed access
PDF file
MBMarco Basset
Marco Basset
IDIrene Defrancesco
Irene Defrancesco
PMPaolo Milani
Paolo Milani
MNMario Nuvolone
Mario Nuvolone
SRSara Rattotti
Sara Rattotti
Giovanni PalladiniGiovanni Palladini
Giovanni Palladini
The authors report on the subset of AL amyloidosis patients with nonlymphoplasmacytic lymphoma, emphasizing a predominance of marginal zone lymphoma, frequent delay in diagnosis, and a generally poor prognosis.

9 September 2019 in American Journal of Hematology
Verified
Journal Article
Closed access
MVMARZIA VARETTONI
MARZIA VARETTONI
EBEmanuela Boveri
Emanuela Boveri
SZSilvia Zibellini
Silvia Zibellini
ATAlessandra Tedeschi
Alessandra Tedeschi
CCChiara Candido
Chiara Candido
LALuca Arcaini
Luca Arcaini

21 February 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CRChiara Rusconi
Chiara Rusconi
AAAntonella Anastasia
Antonella Anastasia
ACAnnalisa Chiarenza
Annalisa Chiarenza
LMLuigi Marcheselli
Luigi Marcheselli
FCFederica CAVALLO
Federica CAVALLO
O(On Behalf Of Fondazione Italiana Linfomi (Fil)
On Behalf Of Fondazione Italiana Linfomi (Fil)
Summary: Optimal treatment for transformed follicular lymphoma (tFL) is not fully defined. Clinical characteristics and treatments that impact on post‐transformation outcome of 176 biopsy‐proven tFL were analysed. Transformation occurred at initial diagnosis in 52% (Group 1) and after a FL diagnosis in 48% (Group 2). Five‐year overall survival was 84% for Group 1 and 51% for Group 2 (P < 0·001). In Group 1, 5‐year progression‐free survival was superior after rituximab maintenance compared to observation only (94% vs. 53%, P = 0·024). In Group 2, an inverse trend was found between survival and both a higher number of pre‐transformation treatment lines and a short time‐to‐transformation.

1 September 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JOJacopo Olivieri
Jacopo Olivieri
FMFederico Mosna
Federico Mosna
MPMatteo Pelosini
Matteo Pelosini
AFAngelo Fama
Angelo Fama
SRSara Rattotti
Sara Rattotti
Francesco ZajaFrancesco Zaja
Francesco Zaja
BEAM (carmustine [bis-chloroethylnitrosourea (BCNU)]-etoposide-cytarabine-melphalan) chemotherapy is the standard conditioning regimen for autologous stem cell transplantation (ASCT) in lymphomas. Owing to BCNU shortages, many centers switched to fotemustine-substituted BEAM (FEAM), lacking proof of equivalence. We conducted a retrospective cohort study in 18 Italian centers to compare the safety and efficacy of BEAM and FEAM regimens for ASCT in lymphomas performed from 2008 to 2015. We enrolled 1038 patients (BEAM = 607, FEAM = 431), of which 27% had Hodgkin lymphoma (HL), 14% indolent non-Hodgkin lymphoma (NHL), and 59% aggressive NHL. Baseline characteristics including age, sex, stage, B-symptoms, extranodal involvement, previous treatments, response before ASCT, and overall conditioning intensity were well balanced between BEAM and FEAM; notable exceptions were median ASCT year (BEAM = 2011 versus FEAM = 2013, P < .001), Sorror score ≥3 (BEAM = 15% versus FEAM = 10%, P = .017), and radiotherapy use (BEAM = 18% versus FEAM = 10%, P < .001). FEAM conditioning resulted in higher rates of gastrointestinal and infectious toxicities, including severe oral mucositis grade ≥3 (BEAM = 31% versus FEAM = 44%, P < .001), and sepsis from Gram-negative bacteria (mean isolates/patient: BEAM = .1 versus FEAM = .19, P < .001). Response status at day 100 post-ASCT (overall response: BEAM = 91% versus FEAM = 88%, P = .42), 2-year overall survival (83.9%; 95% confidence interval [CI], 81.5% to 86.1%) and progression-free survival (70.3%; 95% CI, 67.4% to 73.1%) were not different in the two groups. Mortality from infection was higher in the FEAM group (subhazard ratio, 1.99; 95% CI, 1.02 to 3.88; P = .04). BEAM and FEAM do not appear different in terms of survival and disease control. However, due to concerns of higher toxicity, fotemustine substitution in BEAM does not seem justified, if not for easier supply.